top of page

 
業績|論文・出版物|目次
 

2022

Tumor-targeted fluorescence labeling systems for cancer diagnosis and treatment.

Tazawa H., Shigeyasu K., Noma K., Kagawa S., Sakurai F., Mizuguchi H., Kobayashi H., Imamura T., Fujiwara T.

Cancer Sci., 113, 1919-1929 (2022)

Adenovirus vector-based vaccine for infectious diseases.

Sakurai F., Tachibana M., Mizuguchi H.

Drug Metab. Pharmacokinet., 42, 100432 (2022)

ZFAND3 Overexpression in the Mouse Liver Improves Glucose Tolerance and Hepatic Insulin Resistance.

Shimizu K., Ogiya Y., Yoshinaga K., Kimura H., Michinaga .S, Ono M., Taketomi A., Terada T., Sakurai F., Mizuguchi H., Tomita K., Nishinaka T.

Exp. Clin. Endocrinol. Diabetes, 130, 254-261 (2022)

A dopamine antagonist, domperidone, enhances the replication of an oncolytic adenovirus in human tumor cells.

Nishimae F., Sakurai F., Ono R., Onishi R., Takayama K., Mizuguchi H.

J. Gen. Virol, 103, 1752 (2022)

Adenovirus vector with ADP gene induces cytopathic effects in HEK293 cells without significant elevation of virus titers.

Shiota A., Nishimae F., Sakurai F., Mizuguchi H.

Anticancer Res., 42, 1719-1727 (2022)

Decellularized Organ-Derived Scaffold Is a Promising Carrier for Human Induced Pluripotent Stem Cells-Derived Hepatocytes.

Kojima H., Yagi H., Kushige H., Toda Y., Takayama K., Masuda S., Morisaku T., Tsuchida T., Kuroda K., Hirukawa K., Inui J., Nishi K., Nakano Y., Tanaka M., Hori S., Hasegawa Y., Abe Y., Kitago M., Adachi S., Tomi M., Matsuura K., Mizuguchi H., Kitagawa Y.

Cells, 11, 1258 (2022)

A doxycycline-inducible CYP3A4-Caco-2 cell line as a model for evaluating safety of aflatoxin B1 in the human intestine.

Bai, L., Tachibana, K., Murata, M., Inoue, T., Mizuguchi, H., Maeda, S., Ikemura, K., Okuda, M., Kusakabe, T., Kondoh, M.

Toxicol Lett., 370, 1-6 (2022)

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.

Ono R., Nishimae F., Wakida T., Sakurai F., Mizuguchi H.

Sci. Rep., 12, 21560 (2022)

Modified method for differentiation of myeloid-derived suppressor cells in vitro enhances immunosuppressive ability via glutathione metabolism.

Zhou H., Zhiqi X., Morikawa N., Sakurai F., Mizuguchi H., Okuzaki D., Okada N.. Tachibana M.

Biochem. Biophys. Rep., 33, 101416 (2022)

Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation and tumor infiltration of natural killer cells

Ono R., Sakurai F., Tokuoka S., Ishii K., Mizuguchi H

BioRxiv (2022)

アデノウイルスベクターワクチンの現状と展望

水口裕之、立花雅史、櫻井文教

ドラッグデリバリーシステム, 37, 421-428 (2022)

ヒト35型アデノウイルスを基本骨格とした腫瘍溶解性アデノウイルスの開発

櫻井文教、小野良輔、水口裕之

BIO Clinica, 37, 520-524 (2022)

アデノウイルスベクターワクチン設計のサイエンス ~COVID-19に対するワクチン開発を中心に~

水口裕之

別冊・医学のあゆみ, 83-88 (2022)

bottom of page